GlassScriptPhysician profile
Kinnari Desai
NPI 1790717304
$12,093.53
in general payments reported to CMS, 2019-2025
24 companies · $4,491 in 2025
The $4,491 reported for 2025 was more than what 97% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $41.41 · 2021: $218 · 2022: $147 · 2023: $233 · 2024: $6,781 · 2025: $4,491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,000 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,000 · Food and Beverage: $1,048 · Travel and Lodging: $373 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,000.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,000.00 |
| Food and Beverage | $1,047.69 |
| Travel and Lodging | $372.80 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Distalmotion US | $6,458.58 | 2024 | Dexter L6 Robot |
| Intuitive Surgical, INC. | $4,185.13 | 2019-2025 | |
| Merz North America, INC. | $301.77 | 2023-2025 | Xeomin |
| Astellas Pharma US INC | $178.88 | 2022-2025 | Veozah |
| Allergan, INC. | $169.39 | 2019-2021 | |
| Hologic Sales and Service, LLC | $152.85 | 2021-2025 | Thinprep 2000 Processor, Aptima, Third Wave |
| Abbvie INC. | $132.22 | 2020-2025 | |
| Organon LLC | $77.57 | 2022-2025 | Nexplanon |
| Amgen INC. | $53.96 | 2024-2025 | Evenity, Prolia |
| Medtronic, INC. | $41.22 | 2025 | Truclear |
| Revance Therapeutics, INC. | $40.44 | 2024 | Daxxify |
| Bayer Healthcare Pharmaceuticals INC. | $37.19 | 2022-2025 | |
| Ascend Therapeutics US, LLC | $35.71 | 2021-2023 | |
| Myovant Sciences INC. | $33.68 | 2021 | |
| Merck Sharp & Dohme LLC | $32.95 | 2024 | Keytruda |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $29.13 | 2024 | |
| Millicent US INC | $24.70 | 2024 | Intrarosa |
| Boston Scientific Corporation | $24.69 | 2019 | |
| Sumitomo Pharma America, INC. | $21.22 | 2024 | Myfembree |
| Evofem Biosciences, INC. | $19.90 | 2021 | |
| Laborie Medical Technologies Corp. | $15.42 | 2025 | Eclipse |
| Galderma Laboratories, L.P. | $13.97 | 2019 | |
| Therapeuticsmd, INC. | $12.96 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kinnari Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.